Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Intrapericardial cisplatin for malignant tamponade].

R Pavón Jiménez1, J C García Rubira, J T García Martínez

  • 1Unidad Coronaria. Servicios de Cardiología. Hospital Universitario Virgen Macarena. Sevilla. kaito@arrakis.es

Revista Espanola De Cardiologia
|April 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.

Radiologia·2018
Same author

[Ventricular tachycardia in a young patient].

Revista clinica espanola·2007
Same author

[Enlargement of QT-interval in a patient with coronary disease treated with mianserin].

Anales de medicina interna (Madrid, Spain : 1984)·2003
Same author

[Thromboembolism prevention in acute myocardial infarction].

Revista clinica espanola·2001
Same author

[Spanish Society of Cardiology practice guidelines on arterial hypertension].

Revista espanola de cardiologia·2000
Same author

[Influence of coronary risk factors in secondary prevention: tobacco].

Revista espanola de cardiologia·1999
Same journal

[Early remote monitoring of pacemaker devices and benefits of this paradigm shift. The FAST REMOTE study].

Revista espanola de cardiologia·2023
Same journal

[Cardiopulmonary exercise test in patients with post SARS-CoV-2 sequelae: need to create a multicenter working group. Response].

Revista espanola de cardiologia·2023
Same journal

[Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management].

Revista espanola de cardiologia·2023
Same journal

[Cardiopulmonary exercise test in patients with post SARS-CoV-2 sequelae: need to create a multicenter working group].

Revista espanola de cardiologia·2023
Same journal

[Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment].

Revista espanola de cardiologia·2022
Same journal

[Third-degree atrioventricular block associated with the SARS-CoV-2 mRNA vaccine].

Revista espanola de cardiologia·2022
See all related articles

Intrapericardial cisplatin effectively treats malignant pericardial effusion and prevents recurrence. This safe and painless procedure offers a promising alternative for managing malignant pericardial tamponade.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Context:

  • Malignant pericardial effusion often leads to recurrent cardiac tamponade, necessitating frequent interventions.
  • Current management strategies for malignant pericardial effusion can be cumbersome and have limitations.
  • Pericardiocentesis, while relieving tamponade, has a high rate of fluid reaccumulation.

Purpose:

  • To evaluate the safety and efficacy of intrapericardial cisplatin administration for malignant pericardial tamponade.
  • To assess the recurrence rate of pericardial effusion following intrapericardial cisplatin treatment.
  • To determine the impact of intrapericardial cisplatin on patient survival.

Summary:

  • A study involving 6 patients with malignant pericardial effusion (causes included breast, lung, ovarian cancer, and fibrosarcoma) was conducted.

Related Experiment Videos

  • Intrapericardial cisplatin was administered, resulting in a painless procedure with no reported complications.
  • No recurrences of pericardial effusion were observed, with a mean survival of 5.6 months (range 2-18 months).

    • Impact:

    • Intrapericardial cisplatin demonstrates safety and effectiveness in managing malignant pericardial tamponade.
    • This approach offers a viable method to prevent the reaccumulation of pericardial fluid.
    • The findings suggest a potential improvement in patient outcomes for malignant pericardial effusion.